Kyung‐Bok Son

466 total citations
48 papers, 269 citations indexed

About

Kyung‐Bok Son is a scholar working on Economics and Econometrics, Management of Technology and Innovation and Pharmacology. According to data from OpenAlex, Kyung‐Bok Son has authored 48 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Economics and Econometrics, 18 papers in Management of Technology and Innovation and 11 papers in Pharmacology. Recurrent topics in Kyung‐Bok Son's work include Pharmaceutical Economics and Policy (31 papers), Intellectual Property and Patents (18 papers) and Health Systems, Economic Evaluations, Quality of Life (18 papers). Kyung‐Bok Son is often cited by papers focused on Pharmaceutical Economics and Policy (31 papers), Intellectual Property and Patents (18 papers) and Health Systems, Economic Evaluations, Quality of Life (18 papers). Kyung‐Bok Son collaborates with scholars based in South Korea, Australia and Puerto Rico. Kyung‐Bok Son's co-authors include Tae-Jin Lee, SeungJin Bae, Seung-Sik Hwang, Ruth Lopert, Deborah Gleeson, Donghwan Lee, Inseon S. Choi, Daewon Kim, Jinhee Kim and Tae Jin Lee and has published in prestigious journals such as International Journal of Environmental Research and Public Health, Journal of Physics D Applied Physics and Frontiers in Psychology.

In The Last Decade

Kyung‐Bok Son

42 papers receiving 264 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kyung‐Bok Son South Korea 9 145 75 43 27 25 48 269
Matthew Herder Canada 11 139 1.0× 26 0.3× 48 1.1× 26 1.0× 6 0.2× 55 346
Manoela Manova Bulgaria 10 147 1.0× 17 0.2× 23 0.5× 17 0.6× 8 0.3× 53 314
Tomáš Tesař Slovakia 14 249 1.7× 14 0.2× 14 0.3× 10 0.4× 11 0.4× 49 440
F. Maignen United Kingdom 9 116 0.8× 12 0.2× 15 0.3× 16 0.6× 14 0.6× 24 307
Jay Visaria United States 10 89 0.6× 16 0.2× 5 0.1× 24 0.9× 6 0.2× 23 291
Kiu Tay-Teo Switzerland 5 127 0.9× 5 0.1× 16 0.4× 16 0.6× 12 0.5× 8 307
Genia Long United States 9 294 2.0× 66 0.9× 50 1.2× 3 0.1× 10 0.4× 19 391
Daniel Tobias Michaeli Germany 14 291 2.0× 4 0.1× 17 0.4× 20 0.7× 57 2.3× 48 550
Arora India 7 58 0.4× 8 0.1× 8 0.2× 26 1.0× 4 0.2× 25 231
Ewa Stawowczyk Poland 10 136 0.9× 6 0.1× 11 0.3× 6 0.2× 13 0.5× 23 322

Countries citing papers authored by Kyung‐Bok Son

Since Specialization
Citations

This map shows the geographic impact of Kyung‐Bok Son's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kyung‐Bok Son with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kyung‐Bok Son more than expected).

Fields of papers citing papers by Kyung‐Bok Son

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kyung‐Bok Son. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kyung‐Bok Son. The network helps show where Kyung‐Bok Son may publish in the future.

Co-authorship network of co-authors of Kyung‐Bok Son

This figure shows the co-authorship network connecting the top 25 collaborators of Kyung‐Bok Son. A scholar is included among the top collaborators of Kyung‐Bok Son based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kyung‐Bok Son. Kyung‐Bok Son is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shim, Sung Ryul, et al.. (2025). A Five-Year Analysis of Market Share and Sales Growth for Original Drugs after Patent Expiration in Korea. Therapeutic Innovation & Regulatory Science. 59(2). 349–358.
2.
Son, Kyung‐Bok. (2024). Which factor reduces pharmaceutical expenditure, number of entrants or price variance? Updated generic drug markets in South Korea. Health Economics Review. 14(1). 64–64. 3 indexed citations
3.
Son, Kyung‐Bok, et al.. (2023). Tightened social distancing measures and increased violence during the COVID-19 pandemic in South Korea. Frontiers in Psychology. 14. 1152693–1152693. 2 indexed citations
4.
Son, Kyung‐Bok. (2023). Does the first generic exclusivity system provide an economic incentive for early generic entrance under the patent linkage system?. Frontiers in Public Health. 11. 1120729–1120729. 1 indexed citations
5.
Son, Kyung‐Bok. (2022). Patenting and patent challenges in South Korea after introducing a patent linkage system. Globalization and Health. 18(1). 95–95. 1 indexed citations
6.
Son, Kyung‐Bok, Eui‐Kyung Lee, & Sangwon Lee. (2022). Understanding patient and physician responses to various cost-sharing programs for prescription drugs in South Korea: A multilevel analysis. Frontiers in Public Health. 10. 924992–924992. 1 indexed citations
7.
Son, Kyung‐Bok & Sylvia Park. (2022). Perceptions of Regulatory Decision-Making for New Drugs From the Viewpoints of the Manufacturers in South Korea. Frontiers in Medicine. 9. 869262–869262.
8.
Son, Kyung‐Bok, et al.. (2022). Perceived impact of the patent linkage system on pharmaceutical market from the viewpoint of the domestic manufacturers in South Korea. Globalization and Health. 18(1). 34–34. 1 indexed citations
9.
Son, Kyung‐Bok. (2022). Who initiates price competition when generic entrants are introduced into the South Korean pharmaceutical market?. Frontiers in Public Health. 10. 934161–934161. 1 indexed citations
10.
Son, Kyung‐Bok. (2021). Market Exclusivity of the Originator Drugs in South Korea: A Retrospective Cohort Study. Frontiers in Public Health. 9. 654952–654952. 4 indexed citations
11.
12.
Bae, SeungJin, Hyun‐Jin Choi, Kyung‐Bok Son, et al.. (2021). How can we improve patients’ access to new drugs under uncertainties? : South Korea’s experience with risk sharing arrangements. BMC Health Services Research. 21(1). 967–967. 9 indexed citations
13.
Choi, Inseon S., Donghwan Lee, Kyung‐Bok Son, & SeungJin Bae. (2020). Incidence, cost and gender differences of oropharyngeal and noncervical anogenital cancers in South Korea. BMC Public Health. 20(1). 1035–1035. 10 indexed citations
14.
15.
Park, Jeewon, SeungJin Bae, Tae Jin Lee, & Kyung‐Bok Son. (2020). Marketing and Pricing Strategies of Blockbuster Drugs in the South Korean Market: A 15-Year Retrospective Cohort Study for Choline Alfoscerate. Frontiers in Pharmacology. 11. 232–232. 7 indexed citations
16.
17.
Son, Kyung‐Bok & SeungJin Bae. (2019). Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study. BMJ Open. 9(3). e026603–e026603. 14 indexed citations
18.
Son, Kyung‐Bok. (2019). Importance of the intellectual property system in attempting compulsory licensing of pharmaceuticals: a cross-sectional analysis. Globalization and Health. 15(1). 42–42. 8 indexed citations
19.
Son, Kyung‐Bok, et al.. (2019). Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients. International Journal of Clinical Pharmacy. 41(6). 1434–1441. 2 indexed citations
20.
Son, Kyung‐Bok, Ruth Lopert, Deborah Gleeson, & Tae-Jin Lee. (2018). Moderating the impact of patent linkage on access to medicines: lessons from variations in South Korea, Australia, Canada, and the United States. Globalization and Health. 14(1). 101–101. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Matthew Herder Breakdown of academic impact, for papers by Manoela Manova Breakdown of academic impact, for papers by Tomáš Tesař Breakdown of academic impact, for papers by F. Maignen Breakdown of academic impact, for papers by Jay Visaria Breakdown of academic impact, for papers by Kiu Tay-Teo Breakdown of academic impact, for papers by Genia Long Breakdown of academic impact, for papers by Daniel Tobias Michaeli Breakdown of academic impact, for papers by Arora Breakdown of academic impact, for papers by Ewa Stawowczyk
Rankless by CCL
2026